Compare Jumia Technologies AG - ADR (JMIA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jumia Technologies AG - ADR vs Novo Nordisk A/S — how do they compare? Jumia Technologies AG - ADR trades at $6.33 (market cap $783.99M), while Novo Nordisk A/S trades at $49.4 (market cap $220.53B). The key difference: Novo Nordisk A/S is far larger — about 281.3× Jumia Technologies AG - ADR's market cap, and Novo Nordisk A/S pays a 3.63% dividend while Jumia Technologies AG - ADR pays none. Which is the better fit depends on your goals.
| JMIA | NVO | |
|---|---|---|
Market Cap | $783.99M | $220.53B |
Sector | Consumer Cyclical | Health |
52-Week High | $14.60 | $71.70 |
52-Week Low | $4.45 | $35.29 |
Enterprise Value | $731.09M | $239.49B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JMIA trades at $6.36, down 2.15% today, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue growth to $188.93M in 2025 and narrowing losses, targeting 2027 profitability. Analyst sentiment remains positive with 71% buy ratings despite recent earnings misses. Recent news highlights strong Q1 2026 performance and strategic board appointments.
JMIA presents a high-risk opportunity with significant upside potential if profitability targets are met. The stock faces execution risks in African e-commerce expansion and persistent negative cash flow, but strong revenue growth and analyst support suggest potential for recovery if the 2027 breakeven timeline is achieved.
Novo Nordisk (NVO) trades at $49.68, down 1.27% on the day, amid a bullish technical signal from moving averages. The company demonstrates robust fundamentals with a trailing P/E of 12.08 and a net income margin of 37.2%, supported by three consecutive quarterly earnings beats. Recent positive catalysts include EU and Indian regulatory approvals for its oral Wegovy weight-loss pill, expanding its GLP-1 franchise.
The outlook remains positive given strong analyst consensus (57.9% Buy ratings) and projected earnings growth, though risks include intensifying competition in the weight-loss drug market and potential margin pressure. The stock presents a compelling opportunity for investors seeking exposure to a profitable leader in metabolic diseases.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
